No Data
LUZHU BIOTECH-B (02480.HK) will hold a Board of Directors meeting on March 18 to consider and approve the annual performance.
Gelonghui on March 6 announced that LUZHU BIOTECH-B (02480.HK) will hold a Board of Directors meeting on March 18, 2025 (Tuesday) to consider and approve the group's annual performance for the year ending December 31, 2024, and to discuss the proposal for a final dividend distribution (if any).
LUZHU BIOTECH-B (02480): The application for the license of LZ901 Biological Product has been accepted by the National Medical Products Administration.
LUZHU BIOTECH-B (02480) announced recently that the group's recombinant shingles vaccine (CHO cells) and...
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
The Concept of Innovative Drugs mostly rose, with Shengnuo Pharmaceutical (02257) increasing by 11.56%. Institutions indicate that pharmaceutical innovation is the core driving force of pharmaceutical growth.
Jinwu Finance | Most Innovative Drug Concepts have risen, with Saint Nutra Pharma (02257) up 11.56%, Baiao Saitu (02315) up 9.68%, Geli Pharma (01672) up 7.98%, Lvzhu Bio (02480) up 4.73%, ZAI LAB (09688) up 4.41%, Connaught (02162) up 1.34%, SINO BIOPHARM (01177) up 0.95%, INNOVENT BIO (01801) up 0.69%. Galaxy Securities stated that 1) pharmaceutical innovation is the core driving force of pharmaceutical growth. Innovative drugs have transitioned from Me-too to
Announcement Highlights | Air China Limited has completed the issuance of over 0.85 billion A-shares to AVIC Group; CHINA RES LAND's sales in November increased by nearly 7% year-on-year.
In the first 11 months, SINO-OCEAN GP's cumulative contracted sales amounted to approximately 30.6 billion yuan, with 3.73 billion yuan in contract sales for November; CHINA RES LAND's total contract sales amount for November was approximately 25.8 billion yuan, representing a year-on-year increase of 6.9%.
Green Bamboo Biology - B (02480) spent 0.4824 million Hong Kong dollars to repurchase 0.024 million shares on November 5th.
Green Bamboo Bio-B (02480) announced that on November 5, 2024, the company invested 0.4824 million...
